Fresenius Medical Care Launches FME Reignite with Profit Boost and New Investment Plan Fresenius Medical Care (FME), the world’s leading provider of products and services for people with kidney disease, today unveiled its new FME Reignite strategy at its Capital…
Hippocratic AI, the global leader in safety-focused generative AI agents for healthcare, and Universal Health Services (NYSE: UHS) announced today that GenAI agents that support clinicians by making discharge follow up outreach to patients by phone have been deployed. The…
Abstractive Health has launched Clinical Time Machine, an AI-driven simulation that immerses physicians in diagnostic cases using real historical medical charts. Built on the same HIPAA-compliant platform that powers live summarization of electronic health records (EHRs) in hospital settings, the simulation…
SMART METER SELECTED BY 9AMHEALTH FOR MAJOR EMPLOYER WEIGHT MANAGEMENT PROGRAMS USING CELLULAR WEIGHT SCALE Smart Meter, a pioneer in cellular-enabled weight scale technology, today announced a strategic supply agreement with 9amHealth, a leading provider of comprehensive weight management and…
SynergenX, a national leader revolutionizing hormone therapy, TRT, weight loss, and wellness services, is proud to announce the launch of the SynergenX App, now available for free download on the Apple App Store and Google Play. This user-friendly digital platform is designed to…
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it will not meet the PDUFA goal date for the New Drug Application (NDA) for sebetralstat, the Company’s investigational oral…
Cerus Corporation (Nasdaq: CERS) is proud to announce its celebration of World Blood Donor Day 2025. In 2005, the World Health Assembly designated June 14th as World Blood Donor Day to recognize and thank blood donors across the world for…
Valar Labs, a pioneer in AI-powered diagnostics for oncology, announced the publication of its latest research in European Urology, the highest-impact journal in the field of urology. The peer-reviewed study highlights the performance and clinical impact of Valar Labs’ Vesta platform…
Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today provided a corporate update. “It is especially gratifying that at a…
a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced positive initial results from the target enrollment group in the ongoing ALPHA-SOLAR long-term open-label trial evaluating navenibart (STAR-0215), a monoclonal antibody inhibitor of plasma kallikrein,…
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced new data from its preclinical study of ZL-1503, the Company’s promising IL-13/IL-31R bispecific antibody, demonstrating its ability to simultaneously suppress the inflammatory and pruritogenic (itch-causing) pathways in atopic dermatitis (AD). The findings,…
FDA Approves KEYTRUDA® for PD-L1+ Head & Neck Cancer in Neoadjuvant and Adjuvant Settings Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab), Merck’s…